Hormone Therapy (HRT) Insurance Claim Denied? How to Appeal
Insurance denied hormone therapy for gender transition? Learn your rights under ACA Section 1557, state mandates, and how to appeal with medical necessity documentation.
Hormone therapy — including estrogen, testosterone, progesterone, and anti-androgens — is one of the most common and well-established treatments for gender dysphoria. Despite decades of clinical evidence supporting its safety and effectiveness, insurance companies continue to deny these claims at high rates. If your hormone therapy claim was denied, you have legal rights under federal non-discrimination law, state insurance mandates, and clinical guidelines that directly contradict the insurer's position.
Why Insurers Deny Hormone Therapy Claims
Categorical Gender-Affirming Care Exclusions
Many older insurance plans contain a blanket exclusion for "gender reassignment," "sex reassignment," or "gender-affirming care." These categorical exclusions are legally vulnerable. Under ACA Section 1557 (42 U.S.C. §18116), health programs receiving federal financial assistance cannot discriminate on the basis of sex, which has been consistently interpreted to include gender identity. A categorical exclusion that denies hormone therapy to transgender patients while covering identical medications — the same estrogen, the same testosterone — for cisgender patients constitutes differential treatment based on gender identity.
"Not Medically Necessary" Determinations
Hormone therapy for transgender patients is evidence-based, medically necessary treatment for gender dysphoria (ICD-10: F64.0), a recognized condition in the DSM-5-TR. Every major medical body endorses it as the standard of care, including the American Medical Association, the American Endocrine Society, the World Professional Association for Transgender Health (WPATH Standards of Care, Version 8, 2022), the American Psychiatric Association, and the American College of Obstetricians and Gynecologists. An insurer claiming hormone therapy is "not medically necessary" is directly contradicting the clinical consensus of every relevant major medical organization.
"Experimental" or "Investigational" Denial
Hormone therapy has been prescribed for gender dysphoria for decades and is well-documented in peer-reviewed literature. An "experimental" or "investigational" classification is factually incorrect and directly contradicted by the Endocrine Society's Clinical Practice Guidelines for Gender-Dysphoric/Gender-Incongruent Persons (2017, updated 2023).
erisa-plan-limitations">ERISA Plan Limitations
Self-insured employer plans governed by ERISA are not subject to state insurance mandates. However, ACA §1557 still applies to plans that receive federal financial assistance. Federal employee plans (FEHB) are subject to OPM guidance, which has increasingly supported coverage of gender-affirming care.
State Mandate Non-Compliance
Many states require health insurance plans to cover gender-affirming care including hormone therapy: California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New Jersey, New York, Oregon, Vermont, and Washington, among others. State-regulated (non-ERISA) plans must comply with these mandates.
How to Appeal a Hormone Therapy Denial
Step 1: Identify the Exact Denial Basis
The denial must cite a specific policy exclusion, coverage criterion, or clinical determination. The most common bases are: categorical exclusion of gender-affirming care, not medically necessary, or cosmetic/elective treatment classification. Each requires a different counter-argument.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Step 2: Document That the Same Medications Are Covered for Cisgender Patients
Request the plan's formulary and Schedule of Benefits showing estrogen, testosterone, or related medications as covered drugs. This establishes that the denial is not about coverage of the medication itself, but about the patient's gender identity — the core of the ACA §1557 discrimination argument.
Step 3: Obtain a Letter of Medical Necessity
Your physician or endocrinologist should provide a detailed letter stating your diagnosis (gender dysphoria, ICD-10: F64.0), the specific hormone therapy prescribed with dosage and duration, clinical rationale for the regimen, references to WPATH Standards of Care Version 8 and the Endocrine Society Clinical Practice Guidelines, and a statement that hormone therapy is the recognized standard of medical care for this condition.
Step 4: File the Internal Appeal
Submit within the deadline stated in your denial letter (typically 60 days under ACA §2719). Include the physician's letter of medical necessity, the ACA §1557 non-discrimination argument, state mandate citation if applicable, and documentation that comparable medications are covered for cisgender patients under the same plan.
Step 5: Request External Independent Review: Complete Guide" class="auto-link">External Review
If the internal appeal fails, request external review under ACA §2719. IROs reviewing hormone therapy denials apply clinical standards. Denials that conflict with WPATH guidelines and Endocrine Society practice guidelines are frequently overturned at the external review stage.
Step 6: File Regulatory Complaints
File simultaneously with your state insurance commissioner for state-regulated plans, the Office for Civil Rights at HHS for ACA §1557 violations (hhs.gov/ocr), and the EEOC if the plan is employer-sponsored and the denial constitutes workplace sex discrimination.
What to Include in Your Appeal
- Denial letter with the specific policy exclusion or clinical determination cited
- Physician's letter of medical necessity citing gender dysphoria (ICD-10: F64.0), WPATH Standards of Care Version 8, and Endocrine Society Clinical Practice Guidelines
- Plan's formulary or drug coverage list showing estrogen or testosterone is covered for cisgender patients
- ACA §1557 non-discrimination argument and, if applicable, state mandate documentation
- Complete policy or Summary of Benefits and Coverage showing the categorical exclusion relied upon
Fight Back With ClaimBack
Hormone therapy denials are among the most legally vulnerable decisions insurers make, given the strength of ACA §1557 federal non-discrimination law and the clarity of WPATH and Endocrine Society clinical guidelines. ClaimBack generates a professional appeal letter in 3 minutes, citing the applicable law and your plan-specific documentation.
Start your free claim analysis →
Free analysis · No credit card required · Takes 3 minutes
Related Reading
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides